Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Xencor, Inc.
Pfizer
Tizona Therapeutics, Inc
Novartis
Kura Oncology, Inc.
AstraZeneca
Coherus Oncology, Inc.
National Institutes of Health Clinical Center (CC)
Genentech, Inc.
DEKA Biosciences
Columbia University
Molecure S.A.
Astellas Pharma Inc
Inhibrx Biosciences, Inc
Celldex Therapeutics
Aurigene Discovery Technologies Limited
Corvus Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Syndax Pharmaceuticals
Pfizer
Weill Medical College of Cornell University
Novartis
Syndax Pharmaceuticals
Osaka University
Alliance for Clinical Trials in Oncology
University of Chicago
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Santa Maria Biotherapeutics
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Altor BioScience
Memorial Sloan Kettering Cancer Center
Eisai Inc.
European Organisation for Research and Treatment of Cancer - EORTC